Blood:UCH-L1绕过mTOR促进蛋白质合成和MYC诱导型淋巴瘤的发生

2018-09-27 MedSci MedSci原创

中心点:UCH-L1通过与翻译起始复合物结合和促进其组装来刺激蛋白质翻译。UCH-L1及其催化活性,对MYC诱导的小鼠淋巴瘤至关重要。摘要:mTOR是细胞增殖代谢的中心调控因子。mTOR依赖其结合伴侣,是两种复合物的核心——促进蛋白质合成(mTOR复合物1;mTORC1)和促进存活/增殖信号(mTORC2)。mTORC1下游的蛋白质合成在MYC驱动的肿瘤发生中发挥重要作用,翻译抑制剂越来越受到人们

中心点:

UCH-L1通过与翻译起始复合物结合和促进其组装来刺激蛋白质翻译。

UCH-L1及其催化活性,对MYC诱导的小鼠淋巴瘤至关重要。

摘要:

mTOR是细胞增殖代谢的中心调控因子。mTOR依赖其结合伴侣,是两种复合物的核心——促进蛋白质合成(mTOR复合物1;mTORC1)和促进存活/增殖信号(mTORC2)。

mTORC1下游的蛋白质合成在MYC驱动的肿瘤发生中发挥重要作用,翻译抑制剂越来越受到人们的关注。生发中心B细胞致癌基因UCHL1编码去泛素化酶,通过破坏mTORC1和促进mTORC2组装来调节mTOR复合物之间的平衡。

UCH-L1促进mTORC2依赖性生长存活信号提示其可能在癌症发生过程中发挥正性作用,但其底物4EBP1磷酸化又会促进蛋白质合成,使得UCH-L1对mTORC1活性的抑制作用显得神秘莫测。

为探究上述问题,研究人员采用蛋白质组学分析来鉴别在恶性B细胞中与UCH-L1相关的分子复合物。研究人员发现UCH-L1和翻译起始复合物eIF4F(4EBP1的靶点)之间存在一种新的关系。UCH-L1即可与其结合,又可促进eIF4F组装,并通过其催化活性刺激蛋白质合成。因为mTOR在MYC驱动的肿瘤发生中具有重要作用,研究人员采用新突变型Uchl1转基因小鼠发现,在Eμ-myc模型中,Uchl1加速淋巴瘤发展需要其催化活性。此外,研究人员还证实了缺乏UCH-L1的小鼠可抵抗MYC诱导的淋巴瘤。

总而言之,UCH-L1通过促进翻译起始绕过mTORC1依赖性的蛋白质合成,该机制可能对MYC诱导性B细胞恶性肿瘤至关重要。


原始出处:

Sajjad Hussain,et al. UCH-L1 bypasses mTOR to promote protein biosynthesis and is required for MYC driven lymphomagenesis in mice.Blood  2018  :blood-2018-05-848515;  doi: https://doi.org/10.1182/blood-2018-05-848515

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1796548, encodeId=244f1e965484a, content=<a href='/topic/show?id=88a6180e6a6' target=_blank style='color:#2F92EE;'>#UCH-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18076, encryptionId=88a6180e6a6, topicName=UCH-L1)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Thu Feb 28 22:41:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765740, encodeId=dd351e657406b, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun May 19 05:41:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274816, encodeId=d44412e481604, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Sep 29 11:41:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297054, encodeId=c5f0129e0542a, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Sep 29 11:41:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347047, encodeId=48dc34e04741, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Fri Sep 28 07:33:49 CST 2018, time=2018-09-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1796548, encodeId=244f1e965484a, content=<a href='/topic/show?id=88a6180e6a6' target=_blank style='color:#2F92EE;'>#UCH-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18076, encryptionId=88a6180e6a6, topicName=UCH-L1)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Thu Feb 28 22:41:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765740, encodeId=dd351e657406b, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun May 19 05:41:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274816, encodeId=d44412e481604, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Sep 29 11:41:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297054, encodeId=c5f0129e0542a, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Sep 29 11:41:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347047, encodeId=48dc34e04741, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Fri Sep 28 07:33:49 CST 2018, time=2018-09-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1796548, encodeId=244f1e965484a, content=<a href='/topic/show?id=88a6180e6a6' target=_blank style='color:#2F92EE;'>#UCH-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18076, encryptionId=88a6180e6a6, topicName=UCH-L1)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Thu Feb 28 22:41:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765740, encodeId=dd351e657406b, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun May 19 05:41:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274816, encodeId=d44412e481604, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Sep 29 11:41:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297054, encodeId=c5f0129e0542a, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Sep 29 11:41:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347047, encodeId=48dc34e04741, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Fri Sep 28 07:33:49 CST 2018, time=2018-09-28, status=1, ipAttribution=)]
    2018-09-29 guihongzh
  4. [GetPortalCommentsPageByObjectIdResponse(id=1796548, encodeId=244f1e965484a, content=<a href='/topic/show?id=88a6180e6a6' target=_blank style='color:#2F92EE;'>#UCH-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18076, encryptionId=88a6180e6a6, topicName=UCH-L1)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Thu Feb 28 22:41:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765740, encodeId=dd351e657406b, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun May 19 05:41:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274816, encodeId=d44412e481604, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Sep 29 11:41:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297054, encodeId=c5f0129e0542a, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Sep 29 11:41:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347047, encodeId=48dc34e04741, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Fri Sep 28 07:33:49 CST 2018, time=2018-09-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1796548, encodeId=244f1e965484a, content=<a href='/topic/show?id=88a6180e6a6' target=_blank style='color:#2F92EE;'>#UCH-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18076, encryptionId=88a6180e6a6, topicName=UCH-L1)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Thu Feb 28 22:41:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765740, encodeId=dd351e657406b, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun May 19 05:41:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274816, encodeId=d44412e481604, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Sep 29 11:41:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297054, encodeId=c5f0129e0542a, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Sep 29 11:41:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347047, encodeId=48dc34e04741, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Fri Sep 28 07:33:49 CST 2018, time=2018-09-28, status=1, ipAttribution=)]
    2018-09-28 Jackie Li

    学习

    0

相关资讯

专家“亿”周谈——六年磨一剑:从2012到2018年,BSH套细胞淋巴瘤指南有哪些变化

专家“亿”周谈,英国血液学会(British Society for Haematology,BSH)作为血液肿瘤评估与治疗的权威机构,在2012版MCL指南的基础上,综合近年来MCL研究与治疗的最新成果,使用先进的GRADE体系评估证据水平的强度,将最新的治疗方案进行汇总,编辑成了最新的2018版MCL指南。从2012年到2018,医药界对MCL的治疗取得了哪些突破?梅斯医学荣幸邀请天津医科大学

Blood:PRMT5与BCL6协同发挥致癌作用,对生发中心形成和淋巴瘤细胞存活至关重要

中心点:PRMT5甲基化对BCL6的全转录后的抑制活性以及生发中心形成均至关重要。同时抑制BCL6和PRMT5可协同杀伤表达BCL6的淋巴瘤细胞。摘要:生发中心(GC)反应在产生体液免疫中发挥重要作用,被认为是大多数B细胞淋巴瘤的起源。GC的进出严格受转录因子(如BCL6)的调控。近期,Lu Xiaoqing等人发现PRMT5,对称的二甲基精氨酸甲基转移酶,也在GC形成和亲和力成熟过程中发挥重要作

CSCO 2018:第二代BTK抑制剂Zanubrutinib,持久和特异的靶向亲和力带来更优的疗效和安全性

在9月20日的CSCO会议中,天津医科大学肿瘤医院淋巴瘤科的张会来主任对Zanubrutinib近年来发表的数据进行了介绍,让更多的同道了解到Zanubrutinib的研究进展。

2018 印度专家共识:淋巴瘤的管理

淋巴瘤的临床进程主要取决于疾病的活跃度和侵袭性,淋巴瘤的最佳治疗需要基于正确的诊断以及分类。本文的主要目的是为临床医生针对年龄>18岁成人淋巴瘤患者的临床管理提供指导。主要内容涉及弥漫性大B细胞淋巴瘤,霍奇金淋巴瘤,滤泡性淋巴瘤,T细胞淋巴瘤,慢性淋巴细胞白血病/小淋巴细胞淋巴瘤,伯基特淋巴瘤和间变性大细胞淋巴瘤的详细治疗方案。

Blood:抗CD37嵌合抗原受体T细胞可有效治疗B/T细胞淋巴瘤

嵌合抗原受体(CAR)T细胞已成为B细胞恶性肿瘤患者的新的治疗方式。特别是抗CD19 CAR T细胞疗法,可明显提高B血细胞急性淋巴细胞白血病(ALL)和弥漫性大B细胞淋巴瘤(DLBCL)的临床缓解率。但是,并非所有患者均可获得缓解,并且在所有亚型患者中均有观察到抗原丢失时疾病复发。Irene Scarfò等人于近日在《Blood》杂志上发表一篇文章,介绍了一种针对在B细胞非霍奇金淋巴瘤、慢性淋巴

2018 CSCO:朱军教授:全方位解读CAR-T产品在复发难治性淋巴瘤中的应用现状及前景

2018年9月19-21日,第二十一届全国临床肿瘤学大会暨2018年CSCO学术年会在厦门盛大开幕。作为肿瘤领域的一大热点,CAR-T治疗在今年的CSCO会议上关注度只增不减。北京大学肿瘤医院的朱军教授针对CAR-T治疗国内外获批情况及未来应用前景进行了详细介绍。